The Impact of Nurse Practitioner-Led Multidisciplinary Team Intervention on the Implementation of Guideline-Directed Medical Therapy and Clinical Outcomes in Adults With Multimorbidity

NCT ID: NCT07138183

Last Updated: 2025-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

178 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-31

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether a nurse practitioner-led multidisciplinary team (NP-led MDT) intervention can improve the use of guideline-directed medical therapy (GDMT) and short-term clinical outcomes in hospitalized adults with multimorbidity in a multidisciplinary medicine ward.

The main questions it aims to answer are:

Does NP-led MDT intervention increase the proportion of patients achieving GDMT at hospital discharge?

Does NP-led MDT intervention reduce 30-, 60-, and 90-day readmission, emergency department visits, and mortality?

Researchers will compare the NP-led MDT intervention group with the usual care group to see if the intervention improves GDMT implementation and clinical outcomes.

Participants will:

Be randomly assigned to NP-led MDT care or usual care.

Have their medications reviewed according to the latest guidelines (intervention group only).

Be followed for 90 days after discharge to collect outcomes through medical record review and telephone follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-center, randomized controlled trial designed to evaluate whether a nurse practitioner-led multidisciplinary team (NP-led MDT) intervention can improve the implementation rate of guideline-directed medical therapy (GDMT) and short-term clinical outcomes in hospitalized adults with multimorbidity. Multimorbidity is defined as the coexistence of two or more chronic conditions, including heart failure, hypertension, diabetes mellitus, chronic kidney disease, ischemic heart disease, and chronic obstructive pulmonary disease. Suboptimal use of GDMT is common in this population, contributing to poor clinical outcomes.

Eligible patients admitted from the emergency department to the multidisciplinary medicine ward of a tertiary medical center will be screened within 72 hours of admission. Participants will be randomly assigned in a 1:1 ratio to either the NP-led MDT intervention group or the usual care group.

In the intervention group, the NP-led MDT-comprising a nurse practitioner, physicians, and clinical pharmacists-will review each patient's diagnoses, comorbidities, baseline medications, and relevant laboratory or imaging results. Based on the latest international guidelines, the team will formulate individualized GDMT recommendations, which will be communicated to the patient's primary inpatient care team. The NP will also provide patient and caregiver education on medication adherence, potential side effects, and follow-up requirements. All final prescribing decisions will be made by the primary physician.

In the usual care group, patients will receive standard inpatient management from their primary care team without additional structured NP-led MDT intervention.

The primary outcome is the GDMT implementation rate at hospital discharge, calculated as the number of GDMT drugs prescribed divided by the number indicated according to guidelines. Secondary outcomes include all-cause readmission, emergency department visits, and mortality at 30, 60, and 90 days post-discharge, as well as selected disease-specific clinical indicators when available (e.g., left ventricular ejection fraction, HbA1c, blood pressure, LDL-C, eGFR).

Follow-up will be conducted via medical record review and telephone contact. This trial aims to provide real-world evidence on whether an NP-led MDT approach can bridge the gap between guideline recommendations and actual prescribing practices, thereby improving both medication use and patient outcomes in multimorbid inpatients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multimorbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NP-led MDT Intervention Group

Participants receive care from a nurse practitioner-led multidisciplinary team providing individualized, guideline-based medication recommendations.

Group Type EXPERIMENTAL

NP-led MDT

Intervention Type BEHAVIORAL

a nurse practitioner-led multidisciplinary team (MDT).

Usual Care Group

Participants receive usual inpatient care from the primary care team without additional NP-led MDT intervention.

Group Type ACTIVE_COMPARATOR

Usual Care

Intervention Type BEHAVIORAL

Participants will receive usual inpatient care provided by the primary care team.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NP-led MDT

a nurse practitioner-led multidisciplinary team (MDT).

Intervention Type BEHAVIORAL

Usual Care

Participants will receive usual inpatient care provided by the primary care team.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 18 years or older
2. Admitted to the multidisciplinary ward through the emergency department for inpatient care
3. Diagnosed with at least one of the following six chronic conditions and concurrently having one or more additional chronic diseases:

* Congestive Heart Failure (CHF)
* Diabetes Mellitus (DM)
* Hypertension (HTN)
* Dyslipidemia (DLP)
* Atrial Fibrillation (AF)
* Chronic Kidney Disease (CKD)

Exclusion Criteria

1. End-of-life (EOL) patients: Refers to patients receiving palliative care or those assessed by the medical team as unlikely to survive to discharge during the current hospitalization.
2. Patients expected to be transferred to other departments: For example, patients anticipated to be transferred to oncology, intensive care unit (ICU), surgery, or other departments where full MDT intervention cannot be implemented.
3. Unwilling to participate.
4. Patients under the care of the study team physician on the day of hospitalization.
5. Patients known to be economically or educationally disadvantaged
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

National Taiwan University Clinical Trial Center

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hsiao-Chen Chou Nurse Practitioner

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hsiao-Chen Chou

Role: CONTACT

+886-2-23123456

References

Explore related publications, articles, or registry entries linked to this study.

Spahillari A, Cohen LP, Lin C, Liu Y, Tringale A, Sheppard KE, Ko C, Khairnar R, Williamson KM, Wasfy JH, Scott NS, Paquette C, Greene SJ, Fonarow GC, Januzzi JL Jr. Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic. JACC Heart Fail. 2025 Apr;13(4):554-568. doi: 10.1016/j.jchf.2024.08.017. Epub 2024 Oct 9.

Reference Type BACKGROUND
PMID: 39387769 (View on PubMed)

AlHabeeb W, Alayoubi F, Hayajneh A, Ullah A, Elshaer F. A strategy to improve adherence to guideline-directed medical therapy (GDMT) and the role of the multidisciplinary team in a heart-failure programme. Cardiovasc J Afr. 2024 Jan-Apr 23;35(1):12-15. doi: 10.5830/CVJA-2022-067. Epub 2023 May 5.

Reference Type BACKGROUND
PMID: 37171293 (View on PubMed)

Rao VU, Bhasin A, Vargas J Jr, Arun Kumar V. A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hosp Pract (1995). 2022 Aug;50(3):170-182. doi: 10.1080/21548331.2022.2082776. Epub 2022 Jul 4.

Reference Type BACKGROUND
PMID: 35658810 (View on PubMed)

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. No abstract available.

Reference Type BACKGROUND
PMID: 38490803 (View on PubMed)

Huang PH, Lu YW, Tsai YL, Wu YW, Li HY, Chang HY, Wu CH, Yang CY, Tarng DC, Huang CC, Ho LT, Lin CF, Chien SC, Wu YJ, Yeh HI, Pan WH, Li YH; expert committee for the Taiwan Lipid Guidelines for Primary Prevention. 2022 Taiwan lipid guidelines for primary prevention. J Formos Med Assoc. 2022 Dec;121(12):2393-2407. doi: 10.1016/j.jfma.2022.05.010. Epub 2022 Jun 14.

Reference Type BACKGROUND
PMID: 35715290 (View on PubMed)

Wang TD, Chiang CE, Chao TH, Cheng HM, Wu YW, Wu YJ, Lin YH, Chen MY, Ueng KC, Chang WT, Lee YH, Wang YC, Chu PH, Chao TF, Kao HL, Hou CJ, Lin TH. 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. Acta Cardiol Sin. 2022 May;38(3):225-325. doi: 10.6515/ACS.202205_38(3).20220321A.

Reference Type BACKGROUND
PMID: 35673334 (View on PubMed)

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.

Reference Type BACKGROUND
PMID: 38033089 (View on PubMed)

Li YH, Wang CC, Hung CL, Wu YW, Hsu CH, Tsou YL, Wang CH, Wu CK, Lin PL, Chang HY, Sung SH, Chen ZW, Juang JJ, Wang TD, Chen WJ. 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction. Acta Cardiol Sin. 2024 Mar;40(2):148-171. doi: 10.6515/ACS.202403_40(2).20240206A.

Reference Type BACKGROUND
PMID: 38532817 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202506113RINC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Peer-based Recovery Program
NCT07262411 NOT_YET_RECRUITING NA
The Feasibility of the Peer-based Recovery Program
NCT06897267 ACTIVE_NOT_RECRUITING NA